Drug Trial Radar · NCT06172660
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,750
Planned (sponsor's estimate)
Start
Oct 28, 2024
Primary completion
Dec 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Dec 15, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?
Conditions
- RSV Infection
Interventions
NirsevimabDrug
Immunoprophylaxis against RSV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall effectiveness of RSV immunoprophylaxisTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yale Child Health Research Center
New Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.